[Future directions for antihypertensive drugs].
Mogi
Masaki
M
Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University, Graduate School of Medicine
Min
Li-Juan
LJ
Li
Jian-Mei
JM
Iwai
Masaru
M
Horiuchi
Masatsugu
M
D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage / Q000494:pharmacology; D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000494:pharmacology; D001161:Arteriosclerosis / Q000517:prevention & control; D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D004338:Drug Combinations; D004357:Drug Synergism; D005544:Forecasting; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000008:administration & dosage / Q000494:pharmacology; D009131:Muscle, Smooth, Vascular / Q000166:cytology; D009474:Neurons / Q000166:cytology; D018696:Neuroprotective Agents; D018384:Oxidative Stress
D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D004338:Drug Combinations; D000451:Mineralocorticoid Receptor Antagonists; D018696:Neuroprotective Agents